The active form of vitamin D 3 , 1,25-dihydroxyvitamin D 3 , is a major regulator of bone and calcium homeostasis. In addition, this hormone also inhibits the proliferation and stimulates the differentiation of normal as well as malignant cells. Supraphysiological doses of 1,25-dihydroxyvitamin D 3 are required to reduce cancer cell proliferation. However, these doses will lead in vivo to calcemic side effects such as hypercalcemia and hypercalciuria. During the last 25 years, many structural analogs of 1,25-dihydroxyvitamin D 3 have been synthesized by the introduction of chemical modifications in the A-ring, central CD-ring region or side chain of 1,25-dihydroxyvitamin D 3 in the hope to find molecules with a clear dissociation between the beneficial antiproliferative effects and adverse calcemic side effects. One example of such an analog with a good dissociation ratio is calcipotriol (Daivonex ® ), which is clinically used to treat the hyperproliferative skin disease psoriasis. Other vitamin D analogs were clinically approved for the treatment of osteoporosis or secondary hyperparathyroidism. No vitamin D analog is currently used in the clinic for the treatment of cancer although several analogs have been shown to be potent drugs in animal models of cancer. Transcriptomics studies as well as in vitro cell biological experiments unraveled basic mechanisms involved in the antineoplastic effects of vitamin D and its analogs. 1,25-dihydroxyvitamin D 3 and analogs act in a cell type-and tissue-specific manner. Moreover, a blockade in the transition of the G0/1 toward S phase of the cell cycle, induction of apoptosis, inhibition of migration and invasion of tumor cells together with effects on angiogenesis and inflammation have been implicated in the pleiotropic effects of 1,25-dihydroxyvitamin D 3 and its analogs. In this review we will give an overview of the action of vitamin D analogs in tumor cells and look forward how these compounds could be introduced in the clinical practice.
INTRODUCTION
The active form of vitamin D 3 , 1,25-dihydroxyvitamin D 3 [1α,25(OH) 2 D 3 ; 1] ( Table 1) , is mostly known for its effects on bone, calcium, and phosphate homeostasis. Next to these classical effects, 1,25(OH) 2 D 3 also exerts so-called non-classical effects on various tissues which express the vitamin D receptor (VDR) as well as the enzymes that are responsible for activating the hydroxylations of vitamin D 3 , which is essential for the formation of 1,25(OH) 2 D 3 . Thus, most tissues have the ability to convert vitamin D 3 into its active form, 1,25(OH) 2 D 3 , which in turn will bind the VDR in order to positively or negatively influence target genes via binding of the 1,25(OH) 2 D 3 /VDR complex to vitamin D receptor elements (VDRE). Non-classical properties of 1,25(OH) 2 D 3 include prodifferentiating and antiproliferative effects on normal and cancer cells (Colston et al., 1981; Jensen et al., 2001 ) as well as immunomodulatory effects. However, in order to obtain these non-classical effects, 1,25(OH) 2 D 3 doses of the nanomolar range are necessary, while physiological 1,25(OH) 2 D 3 serum concentrations are in the picomolar range. Since supraphysiological doses of 1,25(OH) 2 D 3 result in hypercalcemia, 1,25(OH) 2 D 3 analogs were developed to minimize the calcemic side effects while preserving or augmenting the beneficial effects of 1,25(OH) 2 D 3 . Both industry and academic institutions have synthesized a vast amount of vitamin D analogs. Some of these analogs have tissue-specific effects with low calcemic side effects and can be given at higher doses compared to the mother compound.
CLINICALLY APPROVED VITAMIN D ANALOGS
Given the huge amount of vitamin D analogs that have been synthesized during the years, it is nearly impossible to give an overview of them all. In the first part we will discuss vitamin D analogs that are clinically approved ( Table 2) . For several conditions such as secondary hyperparathyroidism, psoriasis and osteoporosis, vitamin D analogs are frequently used as a treatment option. Paricalcitol are also used to treat this disease. Secondary hyperparathyroidism is characterized by elevated parathyroid hormone (PTH) levels in response to hypocalcemia and is often caused by chronic kidney disease. Above-mentioned vitamin D analogs suppress PTH, as does 1,25(OH) 2 D 3 , but without inducing severe hypercalcemia. Clinical studies with chronic kidney disease patients show that different analogs induce a stronger PTH suppression compared to placebo treatment (Hamdy et al., 1995; Coburn et al., 2004; Coyne et al., 2006) . Also, end-stage renal disease patients treated with these analogs often have a better survival (Teng et al., 2003;  (Uchiyama et al., 2002) . Various studies in mouse models as well as in patients show that treatment with eldecalcitol [9] leads to higher lumbar and hip bone mineral density and a lower incidence of new vertebral fractures Matsumoto et al., 2011; Harada et al., 2012; Hagino et al., 2013) , making eldecalcitol [9] a very promising new analog for the treatment of osteoporosis.
GENOME-AND TRANSCRIPTOME-WIDE EFFECTS OF VITAMIN D ANALOGS
The exact mechanism of action of vitamin D analogs still has to be deciphered. The reason why specific analogs have superagonistic actions on specific tissues remains unknown, however several studies have tried to elucidate the mechanisms behind these tissue-specific effects. The catabolism of vitamin D analogs is one of the mechanisms that have an effect on their potency. Modifications of the side chain of 1,25(OH) 2 D 3 are known to slow down its catabolism by CYP24A1 (Jones, 1997 (Hansen and Maenpaa, 1997; Kissmeyer et al., 1997; Shankar et al., 1997; Zella et al., 2009 ). The metabolites formed after catabolism of lexicalcitol [12] are more active than the ones formed after 1,25(OH) 2 D 3 is catabolized and this analog is also more effective in slowing down the degradation rate of the VDR (van den Bemd et al., 1996) . Moreover, since some cell types prefer specific catabolism pathways and enzymes above others, the degradation process may also contribute to the tissue-specific activity of vitamin D analogs. The affinity for the vitamin D binding protein (DBP) also plays a role in the activity of vitamin D analogs. Maxacalcitol [5] for example has a 500 times lower affinity for DBP and is thus cleared faster from the circulation than 1,25(OH) 2 D 3 (Okano et al., 1989a) . This analog has a short effect on bone and intestine, tissues responsible for calcium homeostasis, and a longer effect on PTH levels, making this analog ideal for the treatment of secondary hyperparathyroidism. However, it is still unknown why the duration of the effects is different in these tissues. Eldecalcitol [9] on the other hand has a higher DBP affinity compared to the mother compound, leading to longer sustained plasma levels and is thus more suitable for the treatment of osteoporosis (Okano et al., 1989b) .
Another mechanism that contributes to the superagonistic effects of vitamin D analogs is their interaction with the VDR, co-activators and VDREs. 20-epi-1,25(OH) 2 D 3 , a C-20 epimer of 1,25(OH) 2 D 3 [11], promotes heterodimerization between VDR and retinoid X receptor (RXR) (Liu et al., 2001 (Liu et al., 2000; Eelen et al., 2005 Eelen et al., , 2008 Schwinn and DeLuca, 2007 (Danielsson et al., 1996; Quack and Carlberg, 1999 [11] induce VDR binding to CYP24A1 and TRPV6 loci in the intestine, but the analog elicits a prolonged VDR binding to these genes leading to its superagonistic characteristics such as hypercalcemia in vivo (Zella et al., 2009) . Other ChIP studies have tried to investigate the molecular mechanisms of some analogs in different tissues. In osteoblast cell models 2MD [16] bound to the VDR is able to bind VDREs at lower concentrations compared to 1,25(OH) 2 D 3 (Yamamoto et al., 2003) . Seocalcitol [10], on the other hand, mediates the dissociation of Williams syndrome transcription factor of the aromatase promoter leading to inhibition of aromatase expression and activity in breast cancer cells which is one of the main therapeutic strategies in breast cancer patients (Lundqvist et al., 2013) . In a recent paper binding sites of VDR and mothers against decapentaplegic homolog 3 (SMAD3) were investigated in hepatic stellar cells. These transforming growth factor β1 (TGFβ1)-activated cells play an important role in liver fibrosis. In this study it is shown that VDR and SMAD3 can at least transiently co-occupy the same genomic sites and function as enhancers of pro-fibrotic gene expression. However, when calcipotriol [7] is added, the TGFβ1-induced recruitment of SMAD3 is compromised and binding of VDR to these genomic sites is enhanced 10-fold meaning that liganded VDR antagonizes SMAD residency on chromatin and thereby suppresses pro-fibrotic gene expression (Ding et al., 2013) . This genomic feedback circuit is a previously unknown mechanism of calcipotriol [7] .
Micro-array studies in various cancer cell lines such as leukemia, prostate, breast, colorectal, and ovarian cancer show that a variety of gene clusters are influenced by 1,25(OH) 2 D 3 and its analogs (reviewed in Kriebitzsch et al., 2009) . Cell growth, apoptosis, cellular adhesion and extracellular matrix composition, oxidative stress, immune function, intra-and intercellular signaling and steroid/lipid metabolism are frequently modulated processes in cells by 1,25(OH) 2 D 3 and its analogs. However, when different cell lines are compared, few 1,25(OH) 2 D 3 /analogregulated genes overlap, which suggests that 1,25(OH) 2 D 3 and its analogs behave in a cell type-and tissue-specific way. Also studies using human T-cells (Baeke et al., 2011) , rat ventricular heart tissue (Bae et al., 2011) , and bone marrow-derived mouse dendritic cells (Griffin et al., 2004) have researched the impact of 1,25(OH) 2 D 3 analogs on gene expression. In these studies genes important for cell growth, cell death and cell signaling are regulated, but also a large set of genes implicated in the migration of T-cells and dendritic cells are influenced. TX527 [15] imprints human T-cells with a migratory signature and targets them to sites of inflammation (Baeke et al., 2011) . Paricalcitol [2] treatment of rats with cardiac hypertrophy prevents the progression of cardiac hypertrophy and the development into chronic heart failure. The genomic changes associated with cardiac hypertrophy in the ventricular heart tissue of these rats are, in part, reversed by paricalcitol [2] administration (Bae et al., 2011 (Lin et al., 2002) . Also WY1112, a seco-9,11-bisnor-17-methyl analog lacking the C-ring and with a 21-epi side chain which is fluorinated on C26 and C27 [17], was investigated in MCF-7 breast cancer cells. Despite the 400-fold stronger antiproliferative capacity of WY1112 [17], the same genes are upregulated after 1,25(OH) 2 D 3 or WY1112 [17] treatment. However, the induction ability is much higher for the analog (Vanoirbeek et al., 2009) . When treating human coronary artery smooth muscle cells with equal amounts of 1,25(OH) 2 D 3 or paricalcitol [2] the same genes are regulated (Wu-Wong et al., 2007; Shalhoub et al., 2010) . In conclusion, differences in action and capacity of vitamin D analogs are more due to their specific sensitivities to metabolism and their specific interaction with the VDR, co-activators and VDREs than from different gene regulations. However, to our knowledge no studies have yet looked into the potential differences elicited by analogs compared to 1,25(OH) 2 D 3 in the fields of proteomics and epigenetics, which could help to understand the molecular mechanism of 1,25(OH) 2 D 3 and its analogs on different cell and tissue types.
EFFECTS OF VITAMIN D ANALOGS IN CANCER
The use of 1,25(OH) 2 D 3 for the treatment of cancer gained interest since many tissues express vitamin D metabolizing enzymes as well as the VDR and because 1,25(OH) 2 D 3 has potent antiproliferative and prodifferentiating effects on normal and malignant cell lines. Several analogs evaluated in vitro show stronger antiproliferative and prodifferentiating effects compared to the mother compound in different cancer cell lines. These compounds are further evaluated in rodent models to assess their anti-cancer activity and safety in vivo. All in vivo studies using rodent cancer models that were published between 2007 and 2013 are summarized in Table 3 . For studies preceding 2007, the reader is referred to other reviews (Eelen et al., 2007) . In most studies the growth of the tumor is inhibited without inducing severe hypercalcemia when appropriate doses of vitamin D analogs are used (Abe et al., 1991; Kawa et al., 1996 Kawa et al., , 2005 Akhter et al., 1997 , Blutt et al., 2000 Prudencio et al., 2001; Grostern et al., 2002; Flanagan et al., 2003; Albert et al., 2004a; Wietrzyk et al., 2004; Zhang et al., 2005; Fichera et al., 2007; van Ginkel et al., 2007; Ghous et al., 2008; Lee et al., 2008; Schwartz et al., 2008; GonzalezPardo et al., 2010; Seubwai et al., 2010; Berkovich et al., 2013;  
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OH HO For studies preceding 2007 the reader is referred to other reviews (Eelen et al., 2007) . Chiang et al., 2013) . However, in some models the analog dose that is effective in inhibiting tumor growth also causes hypercalcemia and lower survival of the treated animals (Albert et al., 2004b) . Not only tumor proliferation is modulated by vitamin D analogs, also apoptosis, angiogenesis, migration of tumor cells, etc. are affected by some analogs. In xenograft studies where apoptosis in the tumor was investigated after vitamin D analog treatment, apoptosis or the necrotic field in the tumor is augmented (James et al., 1998; VanWeelden et al., 1998; Hara et al., 2001; Vegesna et al., 2003; Lambert et al., 2010; Park et al., 2012) . Inecalcitol (Hybrigenics, France) [14] treatment of mice with squamous cell carcinoma xenografts increases apoptosis in the tumors and this increase is higher for the analog compared to 1,25(OH) 2 D 3 , while the capacity of the analog to inhibit proliferation is equal compared to the mother compound (Ma et al., 2013) . Most studies agree that vitamin D analogs also have an effect on tumor metastasis. Seocalcitol [10] reverses the growth-stimulatory effects of parathyroid hormone-related protein (PTHrP), which plays a major role in prostate cancer progression and metastasis, in a xenograft mouse model of prostate cancer. The same study shows that seocalcitol [10] also inhibits migration and invasion of these prostate cancer cells in vitro (Bhatia et al., 2009 ). This analog also reduces the number and surface area of bone metastasis originating from intracardially injected breast cancer cells (El Abdaimi et al., 2000) . Vitamin D analogs are thus able to reduce the number and growth of metastasis originating from various types of cancer cells (Sato et al., 1984; Lokeshwar et al., 1999; Nakagawa et al., 2005; Park et al., 2012) . However, in a study using mice with chemically induced breast cancer, the invasion capacity of the tumor after seocalcitol [10] treatment is not affected (Liska et al., 2012) . The effect of vitamin D analogs on angiogenesis has also been studied in vivo, but here the results are more conflicting. Some studies show no effect of vitamin D analogs on angiogenesis (Oades et al., 2002; Valrance et al., 2007) , while others find decreased angiogenesis of xenograft tumors. Intraperitoneal injections of inecalcitol [14] decrease the vascularity of xenografted prostate cancer cells (Okamoto et al., 2012) and oral treatment of colorectal tumors in rats with alfacalcidol [8] also inhibits tumor angiogenesis (Iseki et al., 1999) . All in vivo studies conclude that vitamin D analogs inhibit tumor growth but vitamin D and its analogs often do not influence tumor number. Seocalcitol [10] was given as chemoprevention in a transgenic mouse model for androgen-independent prostate cancer. Tumor growth is inhibited, however, there is no prevention in the development of tumors (Perez-Stable et al., 2002) . Since vitamin D and its analogs do not possess cytostatic properties, many in vivo studies have focused on vitamin D analog cancer treatment combined with radiotherapy and/or chemotherapy. When seocalcitol [10] is combined with radiotherapy in a xenograft model for breast cancer, the anti-cancer effects are more effective compared to monotherapy (Sundaram et al., 2003) . Another analog, tacalcitol [6], has been investigated in colorectal cancer xenograft in combination with different standard chemotherapies. Different concentrations as well as administration routes of tacalcitol [6] or PRI-2205 (an analog of calcipotriol)
[18] were used in combination with different concentrations of 5-fluorouracil (5-FU). Using specific analog doses and chemotherapy schedules, a synergistic effect on the prolongation of the life span of the mice is achieved (Milczarek et al., 2013a) . Also the combination with irinotecan or oxaliplatin was investigated. In this study the mice also show a longer life span and a stronger tumor growth inhibition compared to monotherapy when certain doses of tacalcitol [6] and chemotherapy were used. However, some combinations were more toxic than the monotherapies (Milczarek et al., 2013b) . Other studies report better effects when combining calcipotriol [7] and diclofenac in a non-melanoma skin cancer model (Pommergaard et al., 2013) . However, the combination of vitamin D analogs with chemotherapy does not always result in additive or synergistic effects. Combining maxacalcitol [5] and 5-FU did not enhance anti-tumor effects in a chemically induced breast cancer model (Iino et al., 1992) . Another study investigated calcipotriol [7] and its derivatives in breast and lung cancer in vivo models and concluded that these analogs and low dose cytostatics are not effective in the used models (Wietrzyk et al., 2007) . Also tacalcitol [6] in combination with cyclophosphamide does not lead to a significant difference in tumor growth inhibition compared to the vehicle treatment (Wietrzyk et al., 2008) .
In view of the promising results that certain vitamin D analogs show against cancer in vitro and in vivo animal models, some analogs have been tested in cancer patients (Table 4) . Seocalcitol [10] is an analog that has been extensively studied in vitro and in vivo in different cancer models, however in clinical trials the results are rather disappointing. Patients with advanced breast or colon cancer were treated with different doses of seocalcitol [10] (most patients tolerate 7 μg/d) but none of them showed a complete or partial response (Gulliford et al., 1998) . Also oral seocalcitol [10] treatment in patients with inoperable pancreatic cancer exhibited no objective anti-tumor activity (Evans et al., 2002) . Two out of 33 patients with inoperable hepatocellular carcinoma showed a complete response after oral seocalcitol [10] treatment, however the majority of the patients presented stable or progressive disease (Dalhoff et al., 2003) . Inecalcitol [14] is in an early stage II of its clinical trial in chronic lymphocytic leukemia. Fifteen patients received 2 mg/d orally and one patient had a 90% decrease in blood lymphocyte count after 10 months of treatment, in 8 other patients blood lymphocyte count stopped growing when the treatment started (Hybrigenics, 2014) . Intravenous administration of paricalcitol [2], an analog that is approved for secondary hyperparathyroidism, also displayed no objective responses in patients with androgen-independent prostate cancer. However, elevated serum PTH levels, which are common for advanced prostate cancers, are reduced by the analog (Schwartz et al., 2005) . Doxercalciferol [3] , also used in the treatment against secondary hyperparathyroidism, was investigated in androgen-independent prostate cancer patients. A phase I study administered oral doxercalciferol [3] between 5 and 15 μg/d, which was well tolerated by the patients (Liu et al., 2002) . In the following phase II study, patients were treated with 12.5 μg/d for a minimum of 8 weeks and 30% of these patients experienced stable disease for over 6 months (Liu et al., 2003) . Oral treatment of non-Hodgkin's lymphoma patients with 1 μg/d alfacalcidol [8], a pre-metabolite of 1,25(OH) 2 D 3 , resulted in a low overall response. Out of 34 treated patients, only 4 had a complete response and 4 others showed a partial response to the treatment (Raina et al., 1991). Calcipotriol [7] is often used to treat skin psoriasis and has thus been investigated in patients with locally advanced or cutaneous metastases from breast cancer. In both studies the analog was applied topically at a dose of 100 μg/d. One study reported no response after 3 months of treatment (O'Brien et al., 1993) , while in the other study 3 patients showed a 50% reduction in the diameter of treated lesions after 6 weeks (Bower et al., 1991) . A more recently developed analog, , was investigated in 16 patients with advanced solid tumors but no objective response was seen (Jain et al., 2011) . Similar to the in vivo studies, clinical trials have also combined vitamin D analogs with standard radiotherapy or chemotherapy. Metastatic breast cancer patients were given oral paricalcitol [2] doses between 2 and 7 μg/d in combination with taxane-based chemotherapy and this regimen was well tolerated by the patients (Lawrence et al., 2013) . Oral inecalcitol [14] was given to patients with hormone-refractory prostate cancer in combination with docetaxel for maximum 18 weeks. This study had a response rate of 85% based on a PSA decline of at least 30% within 3 months of treatment (Hybrigenics, 2014) . In a small study with acute non-lymphoid leukemia patients the combination of alfacalcidol [8] and chemotherapy resulted in 17% of the patients with a complete response and 45% with a partial response (Petrini et al., 1991) . The same analog was combined with standard treatment of surgery, radiotherapy, and/or chemotherapy in glioblastoma and anaplastic astrocytomas. Here, 0.04 μg/kg/d alfacalcidol [8] was administered resulting in 27% of the patients with progressive regression of the lesion and complete clinical remission (Trouillas et al., 2001) . In metastatic renal cell carcinoma patients, oral treatment of 1 μg alfacalcidol/d [8] Jain et al., 2011 (uncontrolled) was combined with a 3 weekly administration of interferon-α for minimal 3 months. In these patients 25% had a partial response to the combination therapy (Obara et al., 2008 (Gee et al., 2013) . Another study used the same dose in metastatic androgen-independent prostate cancer patients but combined the treatment with docetaxel. Also here, no enhanced PSA response rate or survival rate was seen after 4 weeks of treatment (Attia et al., 2008) . Oral alfacalcidol [8] or placebo was given to patients with myelodysplastic syndromes. In the patients treated with the analog, a prolongation of leukemic transformation-free survival was seen compared to the placebo group (Motomura et al., 1991) . Despite the promising in vitro and in vivo results of vitamin D analogs in cancer models, clinical trials have failed to proof the effects of vitamin D analogs in cancer patients. Vitamin D and its analogs lack cytotoxic activity, so using these analogs in combination with standard therapies such as radio-and chemotherapy is probably more effective than using the analogs as monotherapy. Next to the combination of analogs with standard cancer therapies, it is also possible that these analogs need to be given for a longer period of time or that treatment with analogs has to be started earlier, for example in early stages of disease or even as chemoprevention. 
CONCLUSIONS AND PERSPECTIVES
